(Q38057380)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23121334%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

title

The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23121334%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

0 references

1 reference

ChEBI release 2020-05-28

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23121334%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

Frank I Tarazi

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23121334%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

language of work or name

English

0 references

publication date

4 November 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23121334%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Discovery

16 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23121334%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23121334%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23121334%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

93-103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23121334%20AND%20SRC:MED&resulttype=core&format=json

Asenapine maleate: a new drug for the treatment of schizophrenia and bipolar mania

16 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Iloperidone, asenapine and lurasidone: a primer on their current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Serotonin receptors: their key role in drugs to treat schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Electrophysiological characterization of the effects of asenapine at 5-HT(1A), 5-HT(2A), alpha(2)-adrenergic and D(2) receptors in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Treatment of cognitive dysfunction in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Reboxetine modulates norepinephrine efflux in the frontal cortex of the freely moving rat: the involvement of alpha 2 and 5-HT1A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: The nucleus accumbens shell as a locus of antipsychotic action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

The emerging role of glutamate in the pathophysiology and treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Differential regional and dose-related effects of asenapine on dopamine receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Long-term effects of S(+)N-n-propylnorapomorphine compared with typical and atypical antipsychotics: differential increases of cerebrocortical D2-like and striatolimbic D4-like dopamine receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Paranoid schizophrenia may be caused by dopamine hyperactivity of CA1 hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Asenapine induces differential regional effects on serotonin receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Effects of newer antipsychotics on extrapyramidal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Metabolic risk during antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Serotonin model of schizophrenia: emerging role of glutamate mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Adrenergic targets for the treatment of cognitive deficits in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

A new computer-assisted two-way avoidance conditioning equipment for rats: behavioral and pharmacological validation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Preclinical behavioral models for predicting antipsychotic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Asenapine effects in animal models of psychosis and cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Antidepressant-like activity of amisulpride in two animal models of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Attenuation of chronic mild stress-induced 'anhedonia' by asenapine is not associated with a 'hedonic' profile in intracranial self-stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Improvement of phencyclidine-induced social behaviour deficits in rats: involvement of 5-HT1A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

The role of serotonin receptors in the action of atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

The serotonin-1A receptor in anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

5-HT(1A) receptor function in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Therapeutic options for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

A novel augmentation strategy for treating resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193

Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.738193